<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310750</url>
  </required_header>
  <id_info>
    <org_study_id>B7931001</org_study_id>
    <nct_id>NCT02310750</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation</brief_title>
  <official_title>A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when
      administered to humans. A secondary purpose is to assess what the body does to PF-06700841
      and to assess what PF-06700841 does to the body when given as single and multiple doses. The
      pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and
      solution/suspension forms).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examinations</measure>
    <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
    <description>Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs</measure>
    <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) According to Severity</measure>
    <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
    <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(&lt;) 0.8*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: &lt;0.9*LLN,&gt;1.1*upper limit of normal (ULN); platelets: &lt;0.5*LLN,&gt;1.75*ULN, white blood cell count: &lt;0.6*LLN, &gt;1.5*ULN; lymphocytes, total neutrophils: &lt;0.8*LLN, &gt;1.2*ULN; eosinophils, basophils, monocytes: &gt;1.2*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: &gt;1.1*ULN; liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1</measure>
    <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
    <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
    <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28</measure>
    <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
    <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
    <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</measure>
    <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841</measure>
    <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841</measure>
    <time_frame>Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841</measure>
    <time_frame>MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
    <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841</measure>
    <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
    <description>Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
    <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841</measure>
    <time_frame>pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10</time_frame>
    <description>Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841</measure>
    <time_frame>SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841</measure>
    <time_frame>SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
    <description>MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841</measure>
    <time_frame>SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841</measure>
    <time_frame>SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841</measure>
    <time_frame>MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28</time_frame>
    <description>PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC[tau]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)</measure>
    <time_frame>0-24 hour on Day 10</time_frame>
    <description>Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)</measure>
    <time_frame>0-24 hours on Day 10</time_frame>
    <description>Aetau% was calculated as: 100*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Renal Clearance</measure>
    <time_frame>0-24 hours on Day 10</time_frame>
    <description>Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28</measure>
    <time_frame>Baseline, Day 2, 5, 10, 11, 28</time_frame>
    <description>Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56</measure>
    <time_frame>Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56</time_frame>
    <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28</measure>
    <time_frame>Baseline, Day 2, 5, 10, 11, 28</time_frame>
    <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56</measure>
    <time_frame>Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56</time_frame>
    <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8</measure>
    <time_frame>Baseline, Day 2, 5, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28</measure>
    <time_frame>Baseline, Day 4, 8, 10, 11, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</measure>
    <time_frame>Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8</measure>
    <time_frame>Baseline, Day 2, 5, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28</measure>
    <time_frame>Baseline, Day 4, 8, 10, 11, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</measure>
    <time_frame>Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>PF-06700841 Oral Solution/Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841 oral solution/suspension</intervention_name>
    <description>Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)</description>
    <arm_group_label>PF-06700841 Oral Solution/Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo given during the single ascending and multiple dose periods</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841 tablet</intervention_name>
    <description>PF-06700841 tablet formulation administered during the bioavailability / food effect investigation</description>
    <arm_group_label>PF-06700841 Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Key Inclusion Criteria for Healthy Subject Cohorts:

          -  Healthy male subjects and/or female subjects of non-childbearing potential between the
             ages of 18 and 55 years, inclusive

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

        Key Inclusion Criteria for Psoriasis Subject Cohorts:

          -  Male subjects and/or female subjects of non-childbearing potential with a diagnosis of
             plaque psoriasis who are between the ages of 18 and 65 years, inclusive

          -  Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose

        Exclusion Criteria:

        Key Exclusion Criteria for Healthy Subject Cohorts:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Males of childbearing potential who are unwilling or unable to use a highly effective
             method of contraception as outlined in this protocol for the duration of the study and
             for at least 28 days after the last dose of investigational product

        Key Exclusion Criteria for Psoriasis Subject Cohorts:

          -  Currently have non plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustular
             psoriasis).

          -  Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation
             of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or
             lithium

          -  Males of childbearing potential who are unwilling or unable to use a highly effective
             method of contraception as outlined in this protocol for the duration of the study and
             for at least 28 days after the last dose of investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931001&amp;StudyName=A%20Phase%201%2C%20Within%20Cohort%2C%20Randomized%2C%20Double%20Blind%2C%20Third-party%20Open%2C%20Placebo-controlled%2C%20Single-%20And%20Multiple%20Dose%20Escalation%2C%20Parallel%20Group%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Pf-06700841%20In%20Healthy%20Subjects%20And%20Subjects%20With%20Plaque%20Psoriasis%20And%20Bioavailability%20Of%20A%20Tablet%20Formulation%20Relative%20To%20Suspension%20Formulation%20And%20The%20Effect%20Of%20Food%20On%20A%20Tablet%20Formulation%20Of%20Pf-06700841</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <results_first_submitted>January 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study conducted in 7 Healthy Participant (HP) cohorts: 6 cohorts included Single Ascending Dose (SAD), 4 which continued into Multiple Ascending Dose (MAD) with washout, and a final cohort was tested for food effect (fasted/fed) with washout. 1 multiple dose (MD) cohort in Psoriasis subjects received drug at 2 different dose levels or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="P2">
          <title>PF-­06700841: 3 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="P3">
          <title>PF­-06700841: 10 mg SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 10 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="P4">
          <title>PF-06700841: 30 mg SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 30 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="P5">
          <title>PF­-06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 100 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days, then PF-06700841 tablet 50 mg orally, twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).</description>
        </group>
        <group group_id="P6">
          <title>PF-­06700841: 200 mg SAD Cohort, 175 mg MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 175 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="P7">
          <title>Placebo: SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received placebo matched to PF-06700841 single tablet orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then placebo matched to PF-06700841 tablet once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days followed by placebo matched to PF-06700841 tablet twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).</description>
        </group>
        <group group_id="P8">
          <title>Placebo: MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="P9">
          <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="P10">
          <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="P11">
          <title>PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted</title>
          <description>Participants received PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 2 (9 days) followed by second washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
        <group group_id="P12">
          <title>PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed</title>
          <description>Participants received PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
        <group group_id="P13">
          <title>PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted</title>
          <description>Participants received PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
        <group group_id="P14">
          <title>PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed</title>
          <description>Participants received PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
        <group group_id="P15">
          <title>PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted</title>
          <description>Participants received PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
        <group group_id="P16">
          <title>PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted</title>
          <description>Participants received PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>HP Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>HP Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>HP MAD, Psoriasis MD, HP Fasted/Fed</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>HP Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>HP MAD and Fasted/Fed</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="B2">
          <title>PF-­06700841: 3 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="B3">
          <title>PF­-06700841: 10 mg SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 10 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="B4">
          <title>PF-06700841: 30 mg SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 30 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="B5">
          <title>PF­-06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 100 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days, then PF-06700841 tablet 50 mg orally, twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).</description>
        </group>
        <group group_id="B6">
          <title>PF-­06700841: 200 mg SAD Cohort, 175 mg MAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 175 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).</description>
        </group>
        <group group_id="B7">
          <title>Placebo: SAD Cohort Then MAD Cohort</title>
          <description>Healthy participants received placebo matched to PF-06700841 single tablet orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then placebo matched to PF-06700841 tablet once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days followed by placebo matched to PF-06700841 tablet twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).</description>
        </group>
        <group group_id="B8">
          <title>Placebo: MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="B9">
          <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="B10">
          <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="B11">
          <title>PF-06700841: 100 mg Food Effect Cohort</title>
          <description>All participants who received either PF-06700841 100 mg tablet under fasted condition or PF-06700841 100 mg tablet under fed condition or PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in any 1 of the 6 treatment sequences in food effects cohort of the study.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="13"/>
            <count group_id="B8" value="9"/>
            <count group_id="B9" value="14"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="12"/>
            <count group_id="B12" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-44 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1</title>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>Full analysis set (FAS) included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1</title>
          <population>Full analysis set (FAS) included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine Systolic Blood Pressure (SBP): Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.2" spread="11.97"/>
                    <measurement group_id="O2" value="110.6" spread="6.70"/>
                    <measurement group_id="O3" value="108.7" spread="7.76"/>
                    <measurement group_id="O4" value="102.8" spread="6.62"/>
                    <measurement group_id="O5" value="117.8" spread="9.54"/>
                    <measurement group_id="O6" value="112.4" spread="12.26"/>
                    <measurement group_id="O7" value="115.3" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="6.40"/>
                    <measurement group_id="O2" value="-8.1" spread="9.32"/>
                    <measurement group_id="O3" value="1.0" spread="8.17"/>
                    <measurement group_id="O4" value="9.5" spread="5.96"/>
                    <measurement group_id="O5" value="-1.5" spread="4.64"/>
                    <measurement group_id="O6" value="2.1" spread="11.28"/>
                    <measurement group_id="O7" value="-5.3" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Diastolic blood pressure (DBP): Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="8.55"/>
                    <measurement group_id="O2" value="67.0" spread="8.77"/>
                    <measurement group_id="O3" value="66.2" spread="8.42"/>
                    <measurement group_id="O4" value="58.7" spread="8.19"/>
                    <measurement group_id="O5" value="70.3" spread="7.39"/>
                    <measurement group_id="O6" value="66.9" spread="8.98"/>
                    <measurement group_id="O7" value="70.5" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="7.44"/>
                    <measurement group_id="O2" value="-5.3" spread="9.05"/>
                    <measurement group_id="O3" value="2.2" spread="9.56"/>
                    <measurement group_id="O4" value="4.7" spread="715"/>
                    <measurement group_id="O5" value="2.5" spread="8.83"/>
                    <measurement group_id="O6" value="-0.1" spread="8.36"/>
                    <measurement group_id="O7" value="-2.3" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10</title>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP: Baseline (n=9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.2" spread="9.78"/>
                    <measurement group_id="O2" value="106.5" spread="3.54"/>
                    <measurement group_id="O3" value="103.6" spread="7.64"/>
                    <measurement group_id="O4" value="110.3" spread="5.19"/>
                    <measurement group_id="O5" value="111.5" spread="13.35"/>
                    <measurement group_id="O6" value="108.6" spread="18.45"/>
                    <measurement group_id="O7" value="115.8" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Change at Day 10 (n=9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="9.12"/>
                    <measurement group_id="O2" value="12.5" spread="2.12"/>
                    <measurement group_id="O3" value="-0.2" spread="7.69"/>
                    <measurement group_id="O4" value="8.7" spread="10.69"/>
                    <measurement group_id="O5" value="7.7" spread="12.97"/>
                    <measurement group_id="O6" value="-3.5" spread="8.89"/>
                    <measurement group_id="O7" value="-5.3" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Baseline (n=9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="4.15"/>
                    <measurement group_id="O2" value="61.5" spread="7.78"/>
                    <measurement group_id="O3" value="56.2" spread="4.02"/>
                    <measurement group_id="O4" value="65.5" spread="3.70"/>
                    <measurement group_id="O5" value="68.8" spread="9.06"/>
                    <measurement group_id="O6" value="59.2" spread="16.80"/>
                    <measurement group_id="O7" value="66.2" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Change at Day 10 (n=9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="7.26"/>
                    <measurement group_id="O2" value="6.0" spread="4.24"/>
                    <measurement group_id="O3" value="2.2" spread="6.76"/>
                    <measurement group_id="O4" value="5.7" spread="1.53"/>
                    <measurement group_id="O5" value="3.2" spread="9.62"/>
                    <measurement group_id="O6" value="-4.3" spread="9.14"/>
                    <measurement group_id="O7" value="2.0" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28</title>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP: Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.0" spread="13.21"/>
                    <measurement group_id="O2" value="120.1" spread="10.91"/>
                    <measurement group_id="O3" value="112.9" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="11.87"/>
                    <measurement group_id="O2" value="-8.9" spread="9.94"/>
                    <measurement group_id="O3" value="1.0" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="7.93"/>
                    <measurement group_id="O2" value="69.9" spread="7.94"/>
                    <measurement group_id="O3" value="66.6" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="5.51"/>
                    <measurement group_id="O2" value="-7.0" spread="6.00"/>
                    <measurement group_id="O3" value="-0.8" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1</title>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="6.36"/>
                    <measurement group_id="O2" value="68.6" spread="13.81"/>
                    <measurement group_id="O3" value="67.2" spread="9.66"/>
                    <measurement group_id="O4" value="56.0" spread="8.05"/>
                    <measurement group_id="O5" value="67.3" spread="9.24"/>
                    <measurement group_id="O6" value="55.8" spread="11.77"/>
                    <measurement group_id="O7" value="57.8" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.42"/>
                    <measurement group_id="O2" value="6.1" spread="7.58"/>
                    <measurement group_id="O3" value="2.5" spread="6.28"/>
                    <measurement group_id="O4" value="3.0" spread="8.10"/>
                    <measurement group_id="O5" value="0.7" spread="5.54"/>
                    <measurement group_id="O6" value="-1.1" spread="3.94"/>
                    <measurement group_id="O7" value="2.6" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10</title>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" spread="12.58"/>
                    <measurement group_id="O2" value="59.0" spread="1.41"/>
                    <measurement group_id="O3" value="55.8" spread="7.36"/>
                    <measurement group_id="O4" value="60.8" spread="4.99"/>
                    <measurement group_id="O5" value="61.5" spread="7.50"/>
                    <measurement group_id="O6" value="66.0" spread="9.43"/>
                    <measurement group_id="O7" value="60.5" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 10 (n =9,2,5,3,6,4,4,)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="12.21"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                    <measurement group_id="O3" value="-1.6" spread="5.18"/>
                    <measurement group_id="O4" value="-4.0" spread="7.21"/>
                    <measurement group_id="O5" value="-6.3" spread="8.24"/>
                    <measurement group_id="O6" value="-2.5" spread="4.43"/>
                    <measurement group_id="O7" value="-1.0" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28</title>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" spread="8.07"/>
                    <measurement group_id="O2" value="61.4" spread="9.52"/>
                    <measurement group_id="O3" value="64.9" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="5.38"/>
                    <measurement group_id="O2" value="-5.3" spread="7.41"/>
                    <measurement group_id="O3" value="-3.0" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1</title>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>degree celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.79" spread="0.155"/>
                    <measurement group_id="O2" value="36.83" spread="0.359"/>
                    <measurement group_id="O3" value="36.65" spread="0.187"/>
                    <measurement group_id="O4" value="36.82" spread="0.194"/>
                    <measurement group_id="O5" value="36.80" spread="0.141"/>
                    <measurement group_id="O6" value="36.69" spread="0.164"/>
                    <measurement group_id="O7" value="36.63" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.151"/>
                    <measurement group_id="O2" value="-0.11" spread="0.418"/>
                    <measurement group_id="O3" value="0.35" spread="0.281"/>
                    <measurement group_id="O4" value="0.05" spread="0.235"/>
                    <measurement group_id="O5" value="0.07" spread="0.103"/>
                    <measurement group_id="O6" value="-0.03" spread="0.238"/>
                    <measurement group_id="O7" value="0.05" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10</title>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>degree celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.71" spread="0.136"/>
                    <measurement group_id="O2" value="36.70" spread="0.141"/>
                    <measurement group_id="O3" value="36.76" spread="0.182"/>
                    <measurement group_id="O4" value="36.68" spread="0.126"/>
                    <measurement group_id="O5" value="36.83" spread="0.163"/>
                    <measurement group_id="O6" value="36.76" spread="0.167"/>
                    <measurement group_id="O7" value="36.75" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.228"/>
                    <measurement group_id="O2" value="0.05" spread="0.071"/>
                    <measurement group_id="O3" value="-0.22" spread="0.164"/>
                    <measurement group_id="O4" value="-0.10" spread="0.100"/>
                    <measurement group_id="O5" value="-0.22" spread="0.214"/>
                    <measurement group_id="O6" value="-0.17" spread="0.206"/>
                    <measurement group_id="O7" value="0.05" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28</title>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>degrees celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.74" spread="0.151"/>
                    <measurement group_id="O2" value="36.67" spread="0.213"/>
                    <measurement group_id="O3" value="36.80" spread="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28 (n= 8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.223"/>
                    <measurement group_id="O2" value="-0.04" spread="0.369"/>
                    <measurement group_id="O3" value="-0.20" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change From Baseline in Physical Examinations</title>
        <description>Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.</description>
        <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O14">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O15">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O16">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O17">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O18">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O19">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O20">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Physical Examinations</title>
          <description>Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="14"/>
                <count group_id="O17" value="7"/>
                <count group_id="O18" value="12"/>
                <count group_id="O19" value="12"/>
                <count group_id="O20" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1</title>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>millisecond (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" spread="14.52"/>
                    <measurement group_id="O2" value="149.7" spread="18.62"/>
                    <measurement group_id="O3" value="163.1" spread="13.58"/>
                    <measurement group_id="O4" value="168.2" spread="14.63"/>
                    <measurement group_id="O5" value="163.6" spread="19.37"/>
                    <measurement group_id="O6" value="175.8" spread="18.86"/>
                    <measurement group_id="O7" value="165.9" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="6.78"/>
                    <measurement group_id="O2" value="6.7" spread="8.12"/>
                    <measurement group_id="O3" value="-2.4" spread="6.65"/>
                    <measurement group_id="O4" value="2.2" spread="5.45"/>
                    <measurement group_id="O5" value="-2.1" spread="5.95"/>
                    <measurement group_id="O6" value="3.3" spread="5.62"/>
                    <measurement group_id="O7" value="0.5" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="15.40"/>
                    <measurement group_id="O2" value="92.9" spread="9.30"/>
                    <measurement group_id="O3" value="97.4" spread="10.43"/>
                    <measurement group_id="O4" value="102.9" spread="8.74"/>
                    <measurement group_id="O5" value="99.8" spread="14.61"/>
                    <measurement group_id="O6" value="101.7" spread="6.87"/>
                    <measurement group_id="O7" value="92.0" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="12.73"/>
                    <measurement group_id="O2" value="-1.5" spread="5.98"/>
                    <measurement group_id="O3" value="-2.2" spread="4.06"/>
                    <measurement group_id="O4" value="-1.7" spread="3.55"/>
                    <measurement group_id="O5" value="-2.9" spread="3.45"/>
                    <measurement group_id="O6" value="-2.0" spread="5.19"/>
                    <measurement group_id="O7" value="1.7" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.4" spread="21.42"/>
                    <measurement group_id="O2" value="374.0" spread="21.81"/>
                    <measurement group_id="O3" value="384.3" spread="26.20"/>
                    <measurement group_id="O4" value="404.2" spread="19.89"/>
                    <measurement group_id="O5" value="387.5" spread="12.0"/>
                    <measurement group_id="O6" value="421.3" spread="29.94"/>
                    <measurement group_id="O7" value="407.1" spread="20.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="10.41"/>
                    <measurement group_id="O2" value="-3.8" spread="10.21"/>
                    <measurement group_id="O3" value="-3.1" spread="9.43"/>
                    <measurement group_id="O4" value="-8.2" spread="9.25"/>
                    <measurement group_id="O5" value="-0.8" spread="4.56"/>
                    <measurement group_id="O6" value="-0.8" spread="11.61"/>
                    <measurement group_id="O7" value="-3.3" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.7" spread="16.51"/>
                    <measurement group_id="O2" value="390.9" spread="20.95"/>
                    <measurement group_id="O3" value="400.6" spread="11.90"/>
                    <measurement group_id="O4" value="392.2" spread="13.42"/>
                    <measurement group_id="O5" value="402.7" spread="20.69"/>
                    <measurement group_id="O6" value="400.0" spread="7.60"/>
                    <measurement group_id="O7" value="402.7" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="9.24"/>
                    <measurement group_id="O2" value="-2.3" spread="5.45"/>
                    <measurement group_id="O3" value="-1.9" spread="7.61"/>
                    <measurement group_id="O4" value="2.4" spread="9.42"/>
                    <measurement group_id="O5" value="-4.6" spread="4.41"/>
                    <measurement group_id="O6" value="4.2" spread="7.75"/>
                    <measurement group_id="O7" value="3.2" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10</title>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Baseline (n =9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.9" spread="16.31"/>
                    <measurement group_id="O2" value="180.0" spread="1.41"/>
                    <measurement group_id="O3" value="167.6" spread="10.69"/>
                    <measurement group_id="O4" value="169.0" spread="22.38"/>
                    <measurement group_id="O5" value="168.5" spread="18.79"/>
                    <measurement group_id="O6" value="171.6" spread="14.77"/>
                    <measurement group_id="O7" value="168.0" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Change at Day 10 (n =9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.59"/>
                    <measurement group_id="O2" value="4.7" spread="6.60"/>
                    <measurement group_id="O3" value="7.7" spread="5.36"/>
                    <measurement group_id="O4" value="14.3" spread="8.41"/>
                    <measurement group_id="O5" value="7.3" spread="10.07"/>
                    <measurement group_id="O6" value="11.2" spread="5.14"/>
                    <measurement group_id="O7" value="1.4" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Baseline (n =9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" spread="5.83"/>
                    <measurement group_id="O2" value="96.0" spread="7.07"/>
                    <measurement group_id="O3" value="103.0" spread="9.14"/>
                    <measurement group_id="O4" value="101.0" spread="20.05"/>
                    <measurement group_id="O5" value="102.7" spread="8.52"/>
                    <measurement group_id="O6" value="103.0" spread="8.34"/>
                    <measurement group_id="O7" value="95.2" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Change at Day 10 (n =9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.60"/>
                    <measurement group_id="O2" value="-0.5" spread="6.36"/>
                    <measurement group_id="O3" value="-3.2" spread="9.49"/>
                    <measurement group_id="O4" value="-2.3" spread="6.17"/>
                    <measurement group_id="O5" value="1.3" spread="5.32"/>
                    <measurement group_id="O6" value="2.9" spread="5.26"/>
                    <measurement group_id="O7" value="-1.7" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Baseline (n =9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.9" spread="27.98"/>
                    <measurement group_id="O2" value="425.5" spread="10.61"/>
                    <measurement group_id="O3" value="407.4" spread="18.17"/>
                    <measurement group_id="O4" value="398.0" spread="9.56"/>
                    <measurement group_id="O5" value="399.7" spread="16.12"/>
                    <measurement group_id="O6" value="397.0" spread="23.29"/>
                    <measurement group_id="O7" value="401.8" spread="27.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Change at Day 10 (n =9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="14.72"/>
                    <measurement group_id="O2" value="1.0" spread="11.79"/>
                    <measurement group_id="O3" value="-1.0" spread="23.42"/>
                    <measurement group_id="O4" value="2.6" spread="9.26"/>
                    <measurement group_id="O5" value="1.3" spread="16.66"/>
                    <measurement group_id="O6" value="2.3" spread="5.51"/>
                    <measurement group_id="O7" value="2.1" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Baseline (n =9,2,5,4,6,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.7" spread="11.35"/>
                    <measurement group_id="O2" value="415.5" spread="4.95"/>
                    <measurement group_id="O3" value="396.4" spread="15.53"/>
                    <measurement group_id="O4" value="401.5" spread="15.37"/>
                    <measurement group_id="O5" value="396.0" spread="6.54"/>
                    <measurement group_id="O6" value="403.2" spread="6.26"/>
                    <measurement group_id="O7" value="403.5" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Change at Day 10 (n =9,2,5,3,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="9.82"/>
                    <measurement group_id="O2" value="-1.5" spread="10.14"/>
                    <measurement group_id="O3" value="-2.9" spread="3.00"/>
                    <measurement group_id="O4" value="-5.0" spread="10.49"/>
                    <measurement group_id="O5" value="-1.3" spread="10.34"/>
                    <measurement group_id="O6" value="-0.3" spread="4.46"/>
                    <measurement group_id="O7" value="2.0" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28</title>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28</title>
          <population>FAS included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.4" spread="15.26"/>
                    <measurement group_id="O2" value="156.1" spread="17.78"/>
                    <measurement group_id="O3" value="154.7" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.19"/>
                    <measurement group_id="O2" value="11.1" spread="5.95"/>
                    <measurement group_id="O3" value="4.1" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.6" spread="8.32"/>
                    <measurement group_id="O2" value="97.4" spread="10.27"/>
                    <measurement group_id="O3" value="93.0" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex: Change at Day 28 (n= 8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="4.86"/>
                    <measurement group_id="O2" value="0.8" spread="4.73"/>
                    <measurement group_id="O3" value="3.8" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.4" spread="17.48"/>
                    <measurement group_id="O2" value="411.6" spread="31.01"/>
                    <measurement group_id="O3" value="379.0" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="16.00"/>
                    <measurement group_id="O2" value="-22.6" spread="23.04"/>
                    <measurement group_id="O3" value="-5.3" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Baseline (n=9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.7" spread="14.46"/>
                    <measurement group_id="O2" value="409.0" spread="14.92"/>
                    <measurement group_id="O3" value="392.0" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Interval: Change at Day 28 (n= 8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="10.83"/>
                    <measurement group_id="O2" value="-9.6" spread="7.89"/>
                    <measurement group_id="O3" value="-2.7" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1</title>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="6.83"/>
                    <measurement group_id="O2" value="70.3" spread="16.46"/>
                    <measurement group_id="O3" value="69.2" spread="12.06"/>
                    <measurement group_id="O4" value="55.3" spread="5.65"/>
                    <measurement group_id="O5" value="67.7" spread="8.82"/>
                    <measurement group_id="O6" value="53.0" spread="8.92"/>
                    <measurement group_id="O7" value="58.0" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.74"/>
                    <measurement group_id="O2" value="1.6" spread="2.81"/>
                    <measurement group_id="O3" value="0.3" spread="3.27"/>
                    <measurement group_id="O4" value="4.6" spread="4.64"/>
                    <measurement group_id="O5" value="-2.3" spread="1.72"/>
                    <measurement group_id="O6" value="2.0" spread="3.19"/>
                    <measurement group_id="O7" value="3.4" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10</title>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" spread="7.15"/>
                    <measurement group_id="O2" value="55.5" spread="2.12"/>
                    <measurement group_id="O3" value="55.4" spread="4.45"/>
                    <measurement group_id="O4" value="61.0" spread="2.94"/>
                    <measurement group_id="O5" value="58.5" spread="6.38"/>
                    <measurement group_id="O6" value="63.0" spread="7.38"/>
                    <measurement group_id="O7" value="61.2" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n = 9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="10.33"/>
                    <measurement group_id="O2" value="7.7" spread="6.13"/>
                    <measurement group_id="O3" value="-1.1" spread="7.22"/>
                    <measurement group_id="O4" value="-3.0" spread="4.04"/>
                    <measurement group_id="O5" value="-2.3" spread="5.12"/>
                    <measurement group_id="O6" value="-1.8" spread="5.79"/>
                    <measurement group_id="O7" value="-1.3" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28</title>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28</title>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="9.15"/>
                    <measurement group_id="O2" value="60.2" spread="11.25"/>
                    <measurement group_id="O3" value="66.0" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.28"/>
                    <measurement group_id="O2" value="4.0" spread="8.73"/>
                    <measurement group_id="O3" value="1.4" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.</description>
        <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O14">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O15">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O16">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O17">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O18">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O19">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O20">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="14"/>
                <count group_id="O17" value="7"/>
                <count group_id="O18" value="12"/>
                <count group_id="O19" value="12"/>
                <count group_id="O20" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="5"/>
                    <measurement group_id="O15" value="5"/>
                    <measurement group_id="O16" value="11"/>
                    <measurement group_id="O17" value="6"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="2"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="6"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events (AEs) According to Severity</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild – AEs does not interfere with participant’s usual function b) moderate – AEs interferes to some extent with participant’s usual function c) severe – AEs interferes significantly with participant’s usual function.</description>
        <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O14">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O15">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O16">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O17">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O18">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O19">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O20">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) According to Severity</title>
          <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild – AEs does not interfere with participant’s usual function b) moderate – AEs interferes to some extent with participant’s usual function c) severe – AEs interferes significantly with participant’s usual function.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="14"/>
                <count group_id="O17" value="7"/>
                <count group_id="O18" value="12"/>
                <count group_id="O19" value="12"/>
                <count group_id="O20" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="7"/>
                    <measurement group_id="O16" value="16"/>
                    <measurement group_id="O17" value="16"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="2"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(&lt;) 0.8*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: &lt;0.9*LLN,&gt;1.1*upper limit of normal (ULN); platelets: &lt;0.5*LLN,&gt;1.75*ULN, white blood cell count: &lt;0.6*LLN, &gt;1.5*ULN; lymphocytes, total neutrophils: &lt;0.8*LLN, &gt;1.2*ULN; eosinophils, basophils, monocytes: &gt;1.2*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: &gt;1.1*ULN; liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN)</description>
        <time_frame>SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O14">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O15">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O16">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O17">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O18">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O19">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O20">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <description>Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(&lt;) 0.8*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: &lt;0.9*LLN,&gt;1.1*upper limit of normal (ULN); platelets: &lt;0.5*LLN,&gt;1.75*ULN, white blood cell count: &lt;0.6*LLN, &gt;1.5*ULN; lymphocytes, total neutrophils: &lt;0.8*LLN, &gt;1.2*ULN; eosinophils, basophils, monocytes: &gt;1.2*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: &gt;1.1*ULN; liver function: bilirubin: &gt;1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;3.0*ULN; protein, albumin: &lt;0.8*LLN&gt;&lt;/0&gt;1.2*ULN; renal function:blood urea nitrogen,creatinine: &gt;1.3*ULN; uric acid: &gt;1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN,&gt;1.1*ULN; urinalysis: pH&lt;4.5, &gt;8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: &lt;0.6*LLN,&gt;1.5*ULN)</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="14"/>
                <count group_id="O17" value="7"/>
                <count group_id="O18" value="12"/>
                <count group_id="O19" value="12"/>
                <count group_id="O20" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="7"/>
                    <measurement group_id="O16" value="13"/>
                    <measurement group_id="O17" value="7"/>
                    <measurement group_id="O18" value="5"/>
                    <measurement group_id="O19" value="1"/>
                    <measurement group_id="O20" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1</title>
        <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
        <time_frame>Baseline, 24 hours post-dose on Day 1</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1</title>
          <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>milliliter per minute (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.7" spread="28.70"/>
                    <measurement group_id="O2" value="93.0" spread="36.60"/>
                    <measurement group_id="O3" value="133.8" spread="29.76"/>
                    <measurement group_id="O4" value="95.8" spread="53.07"/>
                    <measurement group_id="O5" value="117.0" spread="28.70"/>
                    <measurement group_id="O6" value="129.6" spread="25.43"/>
                    <measurement group_id="O7" value="114.4" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="63.75"/>
                    <measurement group_id="O2" value="-0.4" spread="35.35"/>
                    <measurement group_id="O3" value="-2.7" spread="11.27"/>
                    <measurement group_id="O4" value="15.8" spread="36.79"/>
                    <measurement group_id="O5" value="-6.4" spread="6.35"/>
                    <measurement group_id="O6" value="-17.6" spread="28.67"/>
                    <measurement group_id="O7" value="73.4" spread="227.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10</title>
        <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
        <time_frame>Baseline, 16 hours post-dose on Day 10</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10</title>
          <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6, 2, 2, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.4" spread="27.75"/>
                    <measurement group_id="O2" value="111.0" spread="1.41"/>
                    <measurement group_id="O3" value="112.6" spread="42.08"/>
                    <measurement group_id="O4" value="115.0" spread="34.13"/>
                    <measurement group_id="O5" value="142.5" spread="56.68"/>
                    <measurement group_id="O6" value="138.4" spread="51.27"/>
                    <measurement group_id="O7" value="83.0" spread="39.73"/>
                    <measurement group_id="O8" value="140.5" spread="55.86"/>
                    <measurement group_id="O9" value="158.0" spread="36.77"/>
                    <measurement group_id="O10" value="172.4" spread="51.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4, 2, 2, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="33.29"/>
                    <measurement group_id="O2" value="-2.5" spread="57.28"/>
                    <measurement group_id="O3" value="26.8" spread="46.90"/>
                    <measurement group_id="O4" value="-19.0" spread="25.51"/>
                    <measurement group_id="O5" value="-47.0" spread="55.68"/>
                    <measurement group_id="O6" value="-39.5" spread="29.86"/>
                    <measurement group_id="O7" value="3.5" spread="40.42"/>
                    <measurement group_id="O8" value="-38.5" spread="60.10"/>
                    <measurement group_id="O9" value="-50.0" spread="4.24"/>
                    <measurement group_id="O10" value="-67.3" spread="61.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28</title>
        <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
        <time_frame>Baseline, 16 hours post-dose on Day 28</time_frame>
        <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28</title>
          <description>Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.</description>
          <population>FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="0.0"/>
                    <measurement group_id="O2" value="-35.0" spread="33.94"/>
                    <measurement group_id="O3" value="-67.6" spread="50.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6463" spread="46"/>
                    <measurement group_id="O2" value="6720" spread="43"/>
                    <measurement group_id="O3" value="5321" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</title>
        <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</title>
          <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6447" spread="46"/>
                    <measurement group_id="O2" value="6694" spread="43"/>
                    <measurement group_id="O3" value="5305" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</title>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</title>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1022" spread="35"/>
                    <measurement group_id="O2" value="1084" spread="40"/>
                    <measurement group_id="O3" value="656.6" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</title>
        <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841</title>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.138" spread="52"/>
                    <measurement group_id="O2" value="18.21" spread="92"/>
                    <measurement group_id="O3" value="79.30" spread="35"/>
                    <measurement group_id="O4" value="271.3" spread="21"/>
                    <measurement group_id="O5" value="748.4" spread="35"/>
                    <measurement group_id="O6" value="2460" spread="37"/>
                    <measurement group_id="O7" value="63.42" spread="11"/>
                    <measurement group_id="O8" value="286.6" spread="17"/>
                    <measurement group_id="O9" value="734.1" spread="29"/>
                    <measurement group_id="O10" value="522.0" spread="31"/>
                    <measurement group_id="O11" value="2091" spread="28"/>
                    <measurement group_id="O12" value="204.7" spread="43"/>
                    <measurement group_id="O13" value="924.2" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841</title>
        <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841</title>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="1.03"/>
                    <measurement group_id="O8" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O9" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O10" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O11" value="0.984" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O12" value="1.00" lower_limit="0.983" upper_limit="1.00"/>
                    <measurement group_id="O13" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-­06700841</title>
        <time_frame>Pre-­dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-­06700841</title>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" spread="0.500" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" spread="1.2965" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O3" value="4.00" spread="1.4383" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0.500" upper_limit="2.00">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="145.8" spread="61" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="353.8" spread="31" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1439" spread="65" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="4797" spread="62" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="18410" spread="46" lower_limit="0.500" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
        <time_frame>MAD: pre­dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post­dose on Day 10; MAD Psoriasis: pre­dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.8" spread="41"/>
                    <measurement group_id="O2" value="1880" spread="52"/>
                    <measurement group_id="O3" value="6089" spread="38"/>
                    <measurement group_id="O4" value="3560" spread="35"/>
                    <measurement group_id="O5" value="16180" spread="15"/>
                    <measurement group_id="O6" value="990.0" spread="103"/>
                    <measurement group_id="O7" value="7672" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</title>
        <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841</title>
          <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.71" spread="114" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O2" value="79.18" spread="239" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="340.4" spread="30" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1431" spread="65" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="5041" spread="59" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="18400" spread="46" lower_limit="0.500" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841</title>
        <description>Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.</description>
        <time_frame>SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841</title>
          <description>Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>[nanogram/milliliter]/milligram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.138" spread="52"/>
                    <measurement group_id="O2" value="6.061" spread="92"/>
                    <measurement group_id="O3" value="7.930" spread="35"/>
                    <measurement group_id="O4" value="9.033" spread="21"/>
                    <measurement group_id="O5" value="7.484" spread="35"/>
                    <measurement group_id="O6" value="12.31" spread="37"/>
                    <measurement group_id="O7" value="6.342" spread="11"/>
                    <measurement group_id="O8" value="9.563" spread="17"/>
                    <measurement group_id="O9" value="7.341" spread="29"/>
                    <measurement group_id="O10" value="10.43" spread="30"/>
                    <measurement group_id="O11" value="11.97" spread="28"/>
                    <measurement group_id="O12" value="6.827" spread="43"/>
                    <measurement group_id="O13" value="9.242" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm.</population>
          <units>[nanogram*hour/milliliter]/milligram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0.500" upper_limit="2.00">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="48.65" spread="61" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="35.38" spread="31" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="47.97" spread="65" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="47.97" spread="62" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="92.13" spread="46" lower_limit="0.500" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841</title>
        <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841</title>
          <description>Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm.</population>
          <units>[ng*hr/mL]/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.71" spread="114" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O2" value="26.38" spread="239" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="34.04" spread="30" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="47.64" spread="65" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="50.41" spread="59" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="92.09" spread="46" lower_limit="0.500" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841</title>
        <description>Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
        <time_frame>pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841</title>
          <description>Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
          <units>[ng*hr/mL]/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.28" spread="41"/>
                    <measurement group_id="O2" value="62.68" spread="51"/>
                    <measurement group_id="O3" value="60.89" spread="38"/>
                    <measurement group_id="O4" value="71.15" spread="36"/>
                    <measurement group_id="O5" value="92.30" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.</description>
        <time_frame>SAD: pre-­dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre­-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre­-dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O14">
            <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O15">
            <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
          <group group_id="O16">
            <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
            <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="12"/>
                <count group_id="O16" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0.500" upper_limit="2.00">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="4.554" spread="1.8066" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="3.848" spread="1.1587" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="4.363" spread="2.4126" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="7.519" spread="2.8236" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="6.813" spread="1.9875" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O7" value="5.928" spread="3.3336" lower_limit="1.00" upper_limit="1.03"/>
                    <measurement group_id="O8" value="4.860" spread="1.9304" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O9" value="10.67" spread="1.8440" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O10" value="9.133" spread="2.2579" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O11" value="7.458" spread="2.1595" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O12" value="16.01" spread="31.584" lower_limit="0.983" upper_limit="2.00"/>
                    <measurement group_id="O13" value="6.032" spread="1.7121" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O14" value="6.155" spread="1.4408" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O15" value="6.168" spread="1.2965" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O16" value="5.848" spread="1.4383" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841</title>
        <description>MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.</description>
        <time_frame>SAD: pre­-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre­-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post­-dose on Day 10; MAD Psoriasis: pre­-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841</title>
          <description>MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="6.414" spread="46"/>
                    <measurement group_id="O3" value="5.169" spread="34"/>
                    <measurement group_id="O4" value="5.206" spread="44"/>
                    <measurement group_id="O5" value="7.277" spread="37"/>
                    <measurement group_id="O6" value="8.758" spread="29"/>
                    <measurement group_id="O7" value="7.191" spread="45"/>
                    <measurement group_id="O8" value="6.830" spread="38"/>
                    <measurement group_id="O9" value="10.35" spread="25"/>
                    <measurement group_id="O10" value="9.592" spread="22"/>
                    <measurement group_id="O11" value="9.025" spread="26"/>
                    <measurement group_id="O12" value="6.072" spread="92"/>
                    <measurement group_id="O13" value="8.534" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0.500" upper_limit="2.00">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="126.4" spread="26" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="151.0" spread="18" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="115.7" spread="16" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O5" value="210.5" spread="45" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="102.4" spread="27" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O7" value="177.6" spread="30" lower_limit="1.00" upper_limit="1.03"/>
                    <measurement group_id="O8" value="106.2" spread="12" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O9" value="249.4" spread="45" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O10" value="180.9" spread="30" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O11" value="112.4" spread="18" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O12" value="245.4" spread="206" lower_limit="0.983" upper_limit="2.00"/>
                    <measurement group_id="O13" value="109.6" spread="18" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.</description>
        <time_frame>SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O10">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O11">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O12">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O13">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O2" value="20.57" spread="61"/>
                    <measurement group_id="O3" value="28.26" spread="31"/>
                    <measurement group_id="O4" value="20.82" spread="65"/>
                    <measurement group_id="O5" value="20.85" spread="61"/>
                    <measurement group_id="O6" value="10.86" spread="46"/>
                    <measurement group_id="O7" value="23.65" spread="41"/>
                    <measurement group_id="O8" value="15.95" spread="51"/>
                    <measurement group_id="O9" value="16.43" spread="38"/>
                    <measurement group_id="O10" value="14.03" spread="35"/>
                    <measurement group_id="O11" value="10.83" spread="16"/>
                    <measurement group_id="O12" value="30.30" spread="103"/>
                    <measurement group_id="O13" value="13.04" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841</title>
        <description>PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC[tau]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
        <time_frame>MAD: pre­-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post­-dose on Day 10; MAD Psoriasis: pre­-dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841</title>
          <description>PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC[tau]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.815" spread="40"/>
                    <measurement group_id="O2" value="3.543" spread="38"/>
                    <measurement group_id="O3" value="2.643" spread="31"/>
                    <measurement group_id="O4" value="1.297" spread="22"/>
                    <measurement group_id="O5" value="2.911" spread="43"/>
                    <measurement group_id="O6" value="3.414" spread="44"/>
                    <measurement group_id="O7" value="2.654" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)</title>
        <description>Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
        <time_frame>0-24 hour on Day 10</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)</title>
          <description>Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
          <units>milligram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.109" spread="45"/>
                    <measurement group_id="O2" value="2.798" spread="57"/>
                    <measurement group_id="O3" value="NA">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O4" value="7.758" spread="57"/>
                    <measurement group_id="O5" value="15.60" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)</title>
        <description>Aetau% was calculated as: 100*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
        <time_frame>0-24 hours on Day 10</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)</title>
          <description>Aetau% was calculated as: 100*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
          <units>percentage of dose recovered</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.09" spread="45"/>
                    <measurement group_id="O2" value="9.332" spread="57"/>
                    <measurement group_id="O3" value="NA">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O4" value="15.54" spread="57"/>
                    <measurement group_id="O5" value="8.910" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Renal Clearance</title>
        <description>Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
        <time_frame>0-24 hours on Day 10</time_frame>
        <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Renal Clearance</title>
          <description>Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.</description>
          <population>PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms.</population>
          <units>Liter per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.619" spread="18"/>
                    <measurement group_id="O2" value="1.486" spread="15"/>
                    <measurement group_id="O3" value="NA">Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.</measurement>
                    <measurement group_id="O4" value="2.179" spread="31"/>
                    <measurement group_id="O5" value="0.9629" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline</title>
        <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
        <time_frame>Baseline</time_frame>
        <population>Pharmacodynamic (PD) analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline</title>
          <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
          <population>Pharmacodynamic (PD) analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.17" spread="40.090"/>
                    <measurement group_id="O2" value="188.76" spread="238.380"/>
                    <measurement group_id="O3" value="219.62" spread="275.440"/>
                    <measurement group_id="O4" value="78.28" spread="29.481"/>
                    <measurement group_id="O5" value="141.38" spread="100.403"/>
                    <measurement group_id="O6" value="115.00" spread="38.458"/>
                    <measurement group_id="O7" value="114.33" spread="26.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28</title>
        <description>Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.</description>
        <time_frame>Baseline, Day 2, 5, 10, 11, 28</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28</title>
          <description>Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.</description>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.04" spread="70.658"/>
                    <measurement group_id="O2" value="85.50" spread="13.011"/>
                    <measurement group_id="O3" value="101.12" spread="56.853"/>
                    <measurement group_id="O4" value="142.23" spread="165.924"/>
                    <measurement group_id="O5" value="106.43" spread="28.244"/>
                    <measurement group_id="O6" value="121.60" spread="20.959"/>
                    <measurement group_id="O7" value="135.42" spread="57.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="13.421"/>
                    <measurement group_id="O2" value="2.00" spread="13.294"/>
                    <measurement group_id="O3" value="-20.14" spread="41.966"/>
                    <measurement group_id="O4" value="-23.60" spread="82.888"/>
                    <measurement group_id="O5" value="-47.52" spread="19.664"/>
                    <measurement group_id="O6" value="-60.64" spread="16.913"/>
                    <measurement group_id="O7" value="-67.73" spread="35.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="12.213"/>
                    <measurement group_id="O2" value="-3.25" spread="13.506"/>
                    <measurement group_id="O3" value="-42.12" spread="48.250"/>
                    <measurement group_id="O4" value="-53.40" spread="125.815"/>
                    <measurement group_id="O5" value="-55.80" spread="15.273"/>
                    <measurement group_id="O6" value="-71.40" spread="11.857"/>
                    <measurement group_id="O7" value="-80.65" spread="66.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="24.123"/>
                    <measurement group_id="O2" value="4.75" spread="9.687"/>
                    <measurement group_id="O3" value="-40.10" spread="43.129"/>
                    <measurement group_id="O4" value="-96.67" spread="134.176"/>
                    <measurement group_id="O5" value="-57.22" spread="9.321"/>
                    <measurement group_id="O6" value="-70.50" spread="14.007"/>
                    <measurement group_id="O7" value="-106.40" spread="60.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.01" spread="19.008"/>
                    <measurement group_id="O2" value="1.85" spread="0.778"/>
                    <measurement group_id="O3" value="-37.56" spread="47.031"/>
                    <measurement group_id="O4" value="-102.53" spread="131.223"/>
                    <measurement group_id="O5" value="-37.95" spread="24.957"/>
                    <measurement group_id="O6" value="-54.25" spread="23.972"/>
                    <measurement group_id="O7" value="-112.20" spread="60.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.59" spread="21.736"/>
                    <measurement group_id="O2" value="2.85" spread="11.102"/>
                    <measurement group_id="O3" value="-11.76" spread="51.955"/>
                    <measurement group_id="O4" value="-62.07" spread="94.378"/>
                    <measurement group_id="O5" value="8.48" spread="23.010"/>
                    <measurement group_id="O6" value="18.30" spread="34.748"/>
                    <measurement group_id="O7" value="-47.15" spread="89.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56</title>
        <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
        <time_frame>Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56</title>
          <description>Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.</description>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.00" spread="281.552"/>
                    <measurement group_id="O2" value="127.58" spread="45.829"/>
                    <measurement group_id="O3" value="123.09" spread="22.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.44" spread="214.334"/>
                    <measurement group_id="O2" value="-8.51" spread="34.704"/>
                    <measurement group_id="O3" value="-49.57" spread="35.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.63" spread="142.195"/>
                    <measurement group_id="O2" value="-33.93" spread="33.465"/>
                    <measurement group_id="O3" value="-49.01" spread="35.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7 (n =9, 12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.71" spread="133.510"/>
                    <measurement group_id="O2" value="-31.31" spread="32.203"/>
                    <measurement group_id="O3" value="-52.50" spread="42.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.91" spread="106.951"/>
                    <measurement group_id="O2" value="-52.06" spread="24.663"/>
                    <measurement group_id="O3" value="-68.55" spread="28.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 21 (n =9, 9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.87" spread="122.986"/>
                    <measurement group_id="O2" value="-51.47" spread="28.094"/>
                    <measurement group_id="O3" value="-46.64" spread="27.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="31.351"/>
                    <measurement group_id="O2" value="-46.19" spread="35.893"/>
                    <measurement group_id="O3" value="-53.36" spread="19.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.20" spread="95.930"/>
                    <measurement group_id="O2" value="-37.50" spread="31.849"/>
                    <measurement group_id="O3" value="-49.34" spread="14.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 35 (n =8, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.54" spread="124.165"/>
                    <measurement group_id="O2" value="10.45" spread="37.860"/>
                    <measurement group_id="O3" value="110.68" spread="108.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 56 (n =7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.71" spread="67.158"/>
                    <measurement group_id="O2" value="16.18" spread="19.348"/>
                    <measurement group_id="O3" value="167.85" spread="201.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline</title>
        <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
        <time_frame>Baseline</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline</title>
          <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1220" spread="0.11909"/>
                    <measurement group_id="O2" value="0.1066" spread="0.09662"/>
                    <measurement group_id="O3" value="0.6420" spread="1.41413"/>
                    <measurement group_id="O4" value="0.0757" spread="0.04523"/>
                    <measurement group_id="O5" value="0.2290" spread="0.11714"/>
                    <measurement group_id="O6" value="0.1158" spread="0.20871"/>
                    <measurement group_id="O7" value="0.1710" spread="0.10387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28</title>
        <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
        <time_frame>Baseline, Day 2, 5, 10, 11, 28</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28</title>
          <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0974" spread="0.06791"/>
                    <measurement group_id="O2" value="0.0815" spread="0.08556"/>
                    <measurement group_id="O3" value="0.1002" spread="0.11675"/>
                    <measurement group_id="O4" value="0.0983" spread="0.03734"/>
                    <measurement group_id="O5" value="0.0505" spread="0.02799"/>
                    <measurement group_id="O6" value="0.0746" spread="0.02523"/>
                    <measurement group_id="O7" value="0.1902" spread="0.06394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n= 9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0148" spread="0.03176"/>
                    <measurement group_id="O2" value="-0.0205" spread="0.00071"/>
                    <measurement group_id="O3" value="-0.0670" spread="0.08196"/>
                    <measurement group_id="O4" value="-0.0408" spread="0.03052"/>
                    <measurement group_id="O5" value="-0.0212" spread="0.01712"/>
                    <measurement group_id="O6" value="-0.0298" spread="0.01743"/>
                    <measurement group_id="O7" value="-0.0307" spread="0.08168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n= 9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0352" spread="0.03847"/>
                    <measurement group_id="O2" value="-0.0050" spread="0.02263"/>
                    <measurement group_id="O3" value="-0.0972" spread="0.11656"/>
                    <measurement group_id="O4" value="-0.0753" spread="0.02269"/>
                    <measurement group_id="O5" value="-0.0435" spread="0.02202"/>
                    <measurement group_id="O6" value="-0.0596" spread="0.03345"/>
                    <measurement group_id="O7" value="-0.1078" spread="0.05948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n= 9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0329" spread="0.05656"/>
                    <measurement group_id="O2" value="0.0015" spread="0.00778"/>
                    <measurement group_id="O3" value="-0.1002" spread="0.11675"/>
                    <measurement group_id="O4" value="-0.0903" spread="0.00961"/>
                    <measurement group_id="O5" value="-0.0467" spread="0.02881"/>
                    <measurement group_id="O6" value="-0.0618" spread="0.01445"/>
                    <measurement group_id="O7" value="-0.1838" spread="0.04529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11 (n= 9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0186" spread="0.07315"/>
                    <measurement group_id="O2" value="-0.0040" spread="0.00990"/>
                    <measurement group_id="O3" value="-0.1002" spread="0.11675"/>
                    <measurement group_id="O4" value="-0.0870" spread="0.00819"/>
                    <measurement group_id="O5" value="-0.0435" spread="0.02849"/>
                    <measurement group_id="O6" value="-0.0615" spread="0.01330"/>
                    <measurement group_id="O7" value="-0.1878" spread="0.04136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n= 9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0496" spread="0.18748"/>
                    <measurement group_id="O2" value="0.0790" spread="0.08910"/>
                    <measurement group_id="O3" value="-0.0352" spread="0.15033"/>
                    <measurement group_id="O4" value="0.0023" spread="0.06001"/>
                    <measurement group_id="O5" value="0.0223" spread="0.01556"/>
                    <measurement group_id="O6" value="-0.0275" spread="0.04086"/>
                    <measurement group_id="O7" value="1.1255" spread="1.63253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56</title>
        <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
        <time_frame>Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56</title>
          <description>Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.</description>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0699" spread="1.39179"/>
                    <measurement group_id="O2" value="0.5694" spread="1.11752"/>
                    <measurement group_id="O3" value="0.3143" spread="0.34167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1096" spread="0.25370"/>
                    <measurement group_id="O2" value="-0.3408" spread="0.86901"/>
                    <measurement group_id="O3" value="-0.0189" spread="0.14180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0204" spread="0.51424"/>
                    <measurement group_id="O2" value="-0.2413" spread="1.45363"/>
                    <measurement group_id="O3" value="-0.2119" spread="0.27245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7 (n =9, 12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1958" spread="0.85725"/>
                    <measurement group_id="O2" value="-0.1573" spread="1.90640"/>
                    <measurement group_id="O3" value="-0.1983" spread="0.31021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4118" spread="1.19190"/>
                    <measurement group_id="O2" value="-0.1910" spread="0.65215"/>
                    <measurement group_id="O3" value="-0.2582" spread="0.33762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 21 (n =9, 9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1397" spread="0.46958"/>
                    <measurement group_id="O2" value="-0.3067" spread="0.61035"/>
                    <measurement group_id="O3" value="-0.2716" spread="0.38954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4075" spread="0.37814"/>
                    <measurement group_id="O2" value="-0.3549" spread="0.69576"/>
                    <measurement group_id="O3" value="-0.2670" spread="0.37674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6113" spread="0.79373"/>
                    <measurement group_id="O2" value="-0.3533" spread="0.69589"/>
                    <measurement group_id="O3" value="-0.2626" spread="0.34387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 35 (n =8, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5945" spread="0.78042"/>
                    <measurement group_id="O2" value="-0.2533" spread="0.79446"/>
                    <measurement group_id="O3" value="0.7546" spread="1.07215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 56 (n =7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3407" spread="0.45280"/>
                    <measurement group_id="O2" value="-0.2662" spread="0.78307"/>
                    <measurement group_id="O3" value="0.2533" spread="0.82107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8</title>
        <time_frame>Baseline, Day 2, 5, 8</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells per millimeter cube (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =13, 7, 6, 6, 6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.988" spread="1.2090"/>
                    <measurement group_id="O2" value="2.433" spread="1.0574"/>
                    <measurement group_id="O3" value="3.097" spread="1.1903"/>
                    <measurement group_id="O4" value="2.500" spread="0.6782"/>
                    <measurement group_id="O5" value="3.048" spread="0.7552"/>
                    <measurement group_id="O6" value="2.973" spread="1.2374"/>
                    <measurement group_id="O7" value="2.858" spread="0.6901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.7459"/>
                    <measurement group_id="O2" value="0.340" spread="0.6643"/>
                    <measurement group_id="O3" value="0.377" spread="0.7133"/>
                    <measurement group_id="O4" value="0.285" spread="0.3214"/>
                    <measurement group_id="O5" value="0.240" spread="0.7344"/>
                    <measurement group_id="O6" value="-0.315" spread="0.8594"/>
                    <measurement group_id="O7" value="-0.760" spread="0.5266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.8048"/>
                    <measurement group_id="O2" value="0.280" spread="0.5187"/>
                    <measurement group_id="O3" value="-0.162" spread="1.1032"/>
                    <measurement group_id="O4" value="-0.170" spread="0.2265"/>
                    <measurement group_id="O5" value="-0.170" spread="0.6963"/>
                    <measurement group_id="O6" value="0.296" spread="0.3849"/>
                    <measurement group_id="O7" value="0.654" spread="0.6930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.245" spread="0.7834"/>
                    <measurement group_id="O2" value="0.196" spread="0.1674"/>
                    <measurement group_id="O3" value="0.017" spread="1.1173"/>
                    <measurement group_id="O4" value="-0.293" spread="0.3100"/>
                    <measurement group_id="O5" value="-0.058" spread="0.9051"/>
                    <measurement group_id="O6" value="-0.110" spread="0.7910"/>
                    <measurement group_id="O7" value="1.188" spread="1.8134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28</title>
        <time_frame>Baseline, Day 4, 8, 10, 11, 14, 28</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.584" spread="0.8858"/>
                    <measurement group_id="O2" value="2.340" spread="0.2970"/>
                    <measurement group_id="O3" value="2.676" spread="0.6726"/>
                    <measurement group_id="O4" value="2.770" spread="0.4907"/>
                    <measurement group_id="O5" value="2.710" spread="1.0372"/>
                    <measurement group_id="O6" value="2.690" spread="0.9337"/>
                    <measurement group_id="O7" value="3.217" spread="0.9677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.4191"/>
                    <measurement group_id="O2" value="0.060" spread="0.0283"/>
                    <measurement group_id="O3" value="-0.242" spread="1.1533"/>
                    <measurement group_id="O4" value="-0.215" spread="0.6376"/>
                    <measurement group_id="O5" value="-0.295" spread="0.8000"/>
                    <measurement group_id="O6" value="-0.980" spread="0.3726"/>
                    <measurement group_id="O7" value="-0.902" spread="2.0680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" spread="0.5725"/>
                    <measurement group_id="O2" value="0.635" spread="1.1526"/>
                    <measurement group_id="O3" value="-0.296" spread="0.7032"/>
                    <measurement group_id="O4" value="-0.178" spread="0.5160"/>
                    <measurement group_id="O5" value="-0.793" spread="0.5720"/>
                    <measurement group_id="O6" value="-0.913" spread="0.4039"/>
                    <measurement group_id="O7" value="-1.702" spread="1.3292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.5860"/>
                    <measurement group_id="O2" value="0.635" spread="1.0394"/>
                    <measurement group_id="O3" value="-0.340" spread="0.8602"/>
                    <measurement group_id="O4" value="0.327" spread="0.8228"/>
                    <measurement group_id="O5" value="-1.012" spread="0.5365"/>
                    <measurement group_id="O6" value="-1.168" spread="0.4197"/>
                    <measurement group_id="O7" value="-2.125" spread="1.2878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" spread="0.4996"/>
                    <measurement group_id="O2" value="0.400" spread="1.2021"/>
                    <measurement group_id="O3" value="-0.382" spread="0.8244"/>
                    <measurement group_id="O4" value="0.260" spread="0.7572"/>
                    <measurement group_id="O5" value="-0.280" spread="0.9159"/>
                    <measurement group_id="O6" value="-0.248" spread="0.3976"/>
                    <measurement group_id="O7" value="-2.010" spread="1.3075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.5471"/>
                    <measurement group_id="O2" value="0.385" spread="0.8273"/>
                    <measurement group_id="O3" value="-0.060" spread="0.8663"/>
                    <measurement group_id="O4" value="0.650" spread="0.8543"/>
                    <measurement group_id="O5" value="0.232" spread="0.4395"/>
                    <measurement group_id="O6" value="0.228" spread="0.3377"/>
                    <measurement group_id="O7" value="0.290" spread="1.0943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.4649"/>
                    <measurement group_id="O2" value="0.130" spread="0.4525"/>
                    <measurement group_id="O3" value="-0.012" spread="1.1401"/>
                    <measurement group_id="O4" value="0.697" spread="0.0839"/>
                    <measurement group_id="O5" value="-0.055" spread="0.4578"/>
                    <measurement group_id="O6" value="0.050" spread="0.6249"/>
                    <measurement group_id="O7" value="0.298" spread="0.3777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</title>
        <time_frame>Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.109" spread="1.4401"/>
                    <measurement group_id="O2" value="3.640" spread="1.4997"/>
                    <measurement group_id="O3" value="3.909" spread="1.1841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.402" spread="0.9308"/>
                    <measurement group_id="O2" value="0.006" spread="1.1696"/>
                    <measurement group_id="O3" value="0.153" spread="0.7114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.209" spread="1.2224"/>
                    <measurement group_id="O2" value="-0.073" spread="0.8229"/>
                    <measurement group_id="O3" value="-0.303" spread="0.6058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =9, 12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.473" spread="0.6962"/>
                    <measurement group_id="O2" value="0.013" spread="1.2572"/>
                    <measurement group_id="O3" value="-0.973" spread="0.4394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 10, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.463" spread="0.7834"/>
                    <measurement group_id="O2" value="0.197" spread="1.1099"/>
                    <measurement group_id="O3" value="-1.299" spread="0.6906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 13 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.654" spread="0.7847"/>
                    <measurement group_id="O2" value="-0.297" spread="1.2264"/>
                    <measurement group_id="O3" value="-1.538" spread="0.9097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.247" spread="0.9682"/>
                    <measurement group_id="O2" value="-0.146" spread="1.1226"/>
                    <measurement group_id="O3" value="-1.465" spread="0.9517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 21 (n =9, 9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.762" spread="0.7389"/>
                    <measurement group_id="O2" value="-0.638" spread="0.9404"/>
                    <measurement group_id="O3" value="-1.410" spread="1.2572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.678" spread="0.6416"/>
                    <measurement group_id="O2" value="-0.890" spread="0.9952"/>
                    <measurement group_id="O3" value="-1.450" spread="1.1195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 35 (n =8, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" spread="1.4496"/>
                    <measurement group_id="O2" value="-0.777" spread="1.1154"/>
                    <measurement group_id="O3" value="-1.008" spread="0.8082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 42 (n =7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.427" spread="0.6004"/>
                    <measurement group_id="O2" value="-0.677" spread="1.1209"/>
                    <measurement group_id="O3" value="-1.050" spread="0.6868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 56 (n =7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.7864"/>
                    <measurement group_id="O2" value="-0.533" spread="1.3025"/>
                    <measurement group_id="O3" value="-0.493" spread="1.6373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8</title>
        <time_frame>Baseline, Day 2, 5, 8</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: SAD Cohort</title>
            <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O2">
            <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-­06700841: 3 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 10 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 30 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 100 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 200 mg SAD Cohort</title>
            <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =13, 7, 6, 6, 6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.470"/>
                    <measurement group_id="O2" value="1.19" spread="0.380"/>
                    <measurement group_id="O3" value="0.98" spread="0.279"/>
                    <measurement group_id="O4" value="1.25" spread="0.243"/>
                    <measurement group_id="O5" value="1.25" spread="0.327"/>
                    <measurement group_id="O6" value="1.44" spread="0.825"/>
                    <measurement group_id="O7" value="1.20" spread="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.152"/>
                    <measurement group_id="O2" value="-0.09" spread="0.135"/>
                    <measurement group_id="O3" value="-0.02" spread="0.160"/>
                    <measurement group_id="O4" value="-0.15" spread="0.138"/>
                    <measurement group_id="O5" value="0.02" spread="0.256"/>
                    <measurement group_id="O6" value="-0.14" spread="0.177"/>
                    <measurement group_id="O7" value="-0.16" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.194"/>
                    <measurement group_id="O2" value="0.07" spread="0.175"/>
                    <measurement group_id="O3" value="-0.05" spread="0.138"/>
                    <measurement group_id="O4" value="-0.27" spread="0.103"/>
                    <measurement group_id="O5" value="0.02" spread="0.409"/>
                    <measurement group_id="O6" value="-0.23" spread="0.459"/>
                    <measurement group_id="O7" value="-0.15" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.234"/>
                    <measurement group_id="O2" value="0.04" spread="0.114"/>
                    <measurement group_id="O3" value="0.03" spread="0.242"/>
                    <measurement group_id="O4" value="-0.15" spread="0.226"/>
                    <measurement group_id="O5" value="0.34" spread="0.532"/>
                    <measurement group_id="O6" value="-0.26" spread="0.478"/>
                    <measurement group_id="O7" value="-0.14" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28</title>
        <time_frame>Baseline, Day 4, 8, 10, 11, 14, 28</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Once Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Twice Daily MAD Cohort</title>
            <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
            <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.490"/>
                    <measurement group_id="O2" value="0.85" spread="0.212"/>
                    <measurement group_id="O3" value="1.22" spread="0.363"/>
                    <measurement group_id="O4" value="1.03" spread="0.350"/>
                    <measurement group_id="O5" value="1.40" spread="0.410"/>
                    <measurement group_id="O6" value="2.26" spread="0.550"/>
                    <measurement group_id="O7" value="1.38" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.212"/>
                    <measurement group_id="O2" value="0.05" spread="0.071"/>
                    <measurement group_id="O3" value="-0.10" spread="0.071"/>
                    <measurement group_id="O4" value="0.05" spread="0.129"/>
                    <measurement group_id="O5" value="-0.18" spread="0.306"/>
                    <measurement group_id="O6" value="-0.54" spread="0.241"/>
                    <measurement group_id="O7" value="-0.32" spread="0.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.285"/>
                    <measurement group_id="O2" value="0.30" spread="0.283"/>
                    <measurement group_id="O3" value="-0.20" spread="0.100"/>
                    <measurement group_id="O4" value="-0.13" spread="0.250"/>
                    <measurement group_id="O5" value="-0.60" spread="0.210"/>
                    <measurement group_id="O6" value="-1.28" spread="0.395"/>
                    <measurement group_id="O7" value="-0.90" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.398"/>
                    <measurement group_id="O2" value="0.20" spread="0.283"/>
                    <measurement group_id="O3" value="-0.24" spread="0.089"/>
                    <measurement group_id="O4" value="-0.07" spread="0.231"/>
                    <measurement group_id="O5" value="-0.70" spread="0.352"/>
                    <measurement group_id="O6" value="-1.48" spread="0.403"/>
                    <measurement group_id="O7" value="-0.93" spread="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.343"/>
                    <measurement group_id="O2" value="0.30" spread="0.424"/>
                    <measurement group_id="O3" value="-0.34" spread="0.089"/>
                    <measurement group_id="O4" value="-0.23" spread="0.115"/>
                    <measurement group_id="O5" value="-0.72" spread="0.354"/>
                    <measurement group_id="O6" value="-1.43" spread="0.499"/>
                    <measurement group_id="O7" value="-0.93" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.393"/>
                    <measurement group_id="O2" value="0.05" spread="0.495"/>
                    <measurement group_id="O3" value="-0.22" spread="0.110"/>
                    <measurement group_id="O4" value="0.03" spread="0.058"/>
                    <measurement group_id="O5" value="-0.60" spread="0.297"/>
                    <measurement group_id="O6" value="-1.10" spread="0.408"/>
                    <measurement group_id="O7" value="-0.90" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.431"/>
                    <measurement group_id="O2" value="-0.05" spread="0.212"/>
                    <measurement group_id="O3" value="0.22" spread="0.277"/>
                    <measurement group_id="O4" value="0.30" spread="0.346"/>
                    <measurement group_id="O5" value="0.65" spread="0.619"/>
                    <measurement group_id="O6" value="0.18" spread="0.189"/>
                    <measurement group_id="O7" value="0.33" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</title>
        <time_frame>Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56</time_frame>
        <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
            <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56</title>
          <population>PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time points for each arm, respectively.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.355"/>
                    <measurement group_id="O2" value="1.45" spread="0.285"/>
                    <measurement group_id="O3" value="1.31" spread="0.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.300"/>
                    <measurement group_id="O2" value="-0.09" spread="0.207"/>
                    <measurement group_id="O3" value="-0.13" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n =9, 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.392"/>
                    <measurement group_id="O2" value="-0.16" spread="0.250"/>
                    <measurement group_id="O3" value="-0.27" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =9, 12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.430"/>
                    <measurement group_id="O2" value="-0.21" spread="0.243"/>
                    <measurement group_id="O3" value="-0.59" spread="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n =9, 10, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.355"/>
                    <measurement group_id="O2" value="-0.35" spread="0.295"/>
                    <measurement group_id="O3" value="-0.70" spread="0.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 13 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.354"/>
                    <measurement group_id="O2" value="-0.41" spread="0.373"/>
                    <measurement group_id="O3" value="-0.75" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n =9, 10, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.371"/>
                    <measurement group_id="O2" value="-0.34" spread="0.392"/>
                    <measurement group_id="O3" value="-0.82" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 21 (n =9, 9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.393"/>
                    <measurement group_id="O2" value="-0.27" spread="0.430"/>
                    <measurement group_id="O3" value="-0.66" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n =8, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.487"/>
                    <measurement group_id="O2" value="-0.36" spread="0.264"/>
                    <measurement group_id="O3" value="-0.60" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 35 (n =8, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.498"/>
                    <measurement group_id="O2" value="-0.03" spread="0.163"/>
                    <measurement group_id="O3" value="0.22" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 42 (n =7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.431"/>
                    <measurement group_id="O2" value="0.33" spread="0.427"/>
                    <measurement group_id="O3" value="1.35" spread="0.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 56 (n =7, 6, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.335"/>
                    <measurement group_id="O2" value="0.07" spread="0.250"/>
                    <measurement group_id="O3" value="0.50" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo: SAD Cohort</title>
          <description>Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Once Daily MAD Cohort</title>
          <description>Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo: Twice Daily MAD Cohort</title>
          <description>Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="E5">
          <title>PF­-06700841: 1 Milligram (mg) SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E6">
          <title>PF-­06700841: 3 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E7">
          <title>PF-06700841: 10 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E8">
          <title>PF-06700841: 10 mg Once Daily MAD Cohort</title>
          <description>Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
        </group>
        <group group_id="E9">
          <title>PF-06700841: 30 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E10">
          <title>PF-06700841: 30 mg Once Daily MAD Cohort</title>
          <description>Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
        </group>
        <group group_id="E11">
          <title>PF-06700841: 100 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E12">
          <title>PF-06700841: 100 mg Once Daily MAD Cohort</title>
          <description>Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
        </group>
        <group group_id="E13">
          <title>PF-06700841: 50 mg Twice Daily MAD Cohort</title>
          <description>Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.</description>
        </group>
        <group group_id="E14">
          <title>PF-06700841: 200 mg SAD Cohort</title>
          <description>Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.</description>
        </group>
        <group group_id="E15">
          <title>PF-06700841: 175 mg Once Daily MAD Cohort</title>
          <description>Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.</description>
        </group>
        <group group_id="E16">
          <title>PF-06700841: 30 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="E17">
          <title>PF-06700841: 100 mg MAD Psoriasis Cohort</title>
          <description>Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.</description>
        </group>
        <group group_id="E18">
          <title>PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)</title>
          <description>All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
        </group>
        <group group_id="E19">
          <title>PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)</title>
          <description>All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
        </group>
        <group group_id="E20">
          <title>PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)</title>
          <description>All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquires@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

